Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities.
Matareed M, Maranou E, Koskela SA, Mehmood A, Kalirai H, Coupland SE, Figueiredo CR. J Pathol. 2023 Feb 24. doi: 10.1002/path.6076. Epub ahead of print. PMID: 36825655.
Using the Chick Embryo Model to Examine the Effects of Hypoxia Pre-conditioning of Uveal Melanoma Cells on Tumor Growth and Metastasis.
Draper J, Alexander J, Nair RM, Scullion N, Narayana RVL, Aughton K, Herrmann A, Vemuganti GK, Kalirai H, Coupland SE. Curr Eye Res. 2023 Apr;48(4):408-415. Erratum in: Curr Eye Res. 2023 Mar 20;:1. PMID: 36484268.
1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model.
Slater K, Bosch R, Smith KF, Jahangir CA, Garcia-Mulero S, Rahman A, O'Connell F, Piulats JM, O'Neill V, Horgan N, Coupland SE, O'Sullivan J, Gallagher WM, Villanueva A, Kennedy BN. Front Med (Lausanne). 2023 Jan 9;9:1036322.
Slater K, Bosch R, Smith KF, Jahangir CA, Garcia-Mulero S, Rahman A, O'Connell F, Piulats JM, O'Neill V, Horgan N, Coupland SE, O'Sullivan J, Gallagher WM, Villanueva A, Kennedy BN. Front Med (Lausanne). 2023 Jan 9;9:1036322.
Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging.
Tomar AS, et al. American Joint Committee on Cancer Ophthalmic Oncology Task Force; American Joint Committee on Cancer Ophthalmic Oncology Task. Br J Ophthalmol. 2023 Jan;107(1):127-132.
Tomar AS, et al. American Joint Committee on Cancer Ophthalmic Oncology Task Force; American Joint Committee on Cancer Ophthalmic Oncology Task. Br J Ophthalmol. 2023 Jan;107(1):127-132.
Ruthenium106 plaque brachytherapy for uveal leiomyoma: a new approach to treatment?
Eibenberger K, Hussain R, Krishna Y, Coupland SE, Heimann H. Eye (Lond). 2023 Apr;37(5):1042-1044.
Eibenberger K, Hussain R, Krishna Y, Coupland SE, Heimann H. Eye (Lond). 2023 Apr;37(5):1042-1044.
McGrath LA, Ryan DA, Warrier SK, Coupland SE, Glasson WJ. Eye (Lond). 2023 Apr;37(5):837-848.
Retinoinvasive amelanotic ring melanoma of the ciliary body.
Lemaître S, Thaung C, Coupland SE, Sagoo MS. Can J Ophthalmol. 2023 Apr 17:S0008-4182(23)00103-5.
Lemaître S, Thaung C, Coupland SE, Sagoo MS. Can J Ophthalmol. 2023 Apr 17:S0008-4182(23)00103-5.
Sensitivity and Specificity of Different Prognostic Systems in Guiding Surveillance for Metastases in Uveal Melanoma.
Robinson H, Eleuteri A, Sacco JJ, Hussain R, Heimann H, Taktak AFG, Damato B, Thompson AJ, Allen T, Kalirai H, Coupland SE. Cancers (Basel). 2023 May 4;15(9):2610.
Robinson H, Eleuteri A, Sacco JJ, Hussain R, Heimann H, Taktak AFG, Damato B, Thompson AJ, Allen T, Kalirai H, Coupland SE. Cancers (Basel). 2023 May 4;15(9):2610.
Tumor-associated retinal pigmentation (TARP) in choroidal melanoma.
Wallace A, Krishna Y, Coupland SE, Heimann H, Diafas A, Hussain RN.Ophthalmology. 2023 May 12:S0161-6420(23)00345-7.
Wallace A, Krishna Y, Coupland SE, Heimann H, Diafas A, Hussain RN.Ophthalmology. 2023 May 12:S0161-6420(23)00345-7.
Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery.
Yin J, Zhao G, Kalirai H, Coupland SE, Jochemsen AG, Forn-Cuní G, Wierenga APA, Jager MJ, Snaar-Jagalska BE, Groenewoud A. Pharmaceuticals (Basel). 2023 Apr 15;16(4):598.
Yin J, Zhao G, Kalirai H, Coupland SE, Jochemsen AG, Forn-Cuní G, Wierenga APA, Jager MJ, Snaar-Jagalska BE, Groenewoud A. Pharmaceuticals (Basel). 2023 Apr 15;16(4):598.
Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer.
Williams CJM, Elliott F, Sapanara N, Aghaei F, Zhang L, Muranyi A, Yan D, Bai I, Zhao Z, Shires M, Wood HM, Richman SD, Hemmings G, Hale M, Bottomley D, Galvin L, Cartlidge C, Dance S, Bacon CM, Mansfield L, Young-Zvandasara K, Sudan A, Lambert K, Bibby I, Coupland SE, Montazeri A, Kipling N, Hughes K, Cross SS, Dewdney A, Pheasey L, Leng C, Gochera T, Mangham DC, Saunders M, Pritchard M, Stott H, Mukherjee A, Ilyas M, Silverman R, Hyland G, Sculthorpe D, Thornton K, Gould I, O'Callaghan A, Brown N, Turnbull S, Shaw L, Seymour MT, West NP, Seligmann JF, Singh S, Shanmugam K, Quirke P. Clin Cancer Res. 2023 Jun 26:CCR-23-0859.
Williams CJM, Elliott F, Sapanara N, Aghaei F, Zhang L, Muranyi A, Yan D, Bai I, Zhao Z, Shires M, Wood HM, Richman SD, Hemmings G, Hale M, Bottomley D, Galvin L, Cartlidge C, Dance S, Bacon CM, Mansfield L, Young-Zvandasara K, Sudan A, Lambert K, Bibby I, Coupland SE, Montazeri A, Kipling N, Hughes K, Cross SS, Dewdney A, Pheasey L, Leng C, Gochera T, Mangham DC, Saunders M, Pritchard M, Stott H, Mukherjee A, Ilyas M, Silverman R, Hyland G, Sculthorpe D, Thornton K, Gould I, O'Callaghan A, Brown N, Turnbull S, Shaw L, Seymour MT, West NP, Seligmann JF, Singh S, Shanmugam K, Quirke P. Clin Cancer Res. 2023 Jun 26:CCR-23-0859.
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities.
Wang MM, Coupland SE, Aittokallio T, Figueiredo CR.Br J Cancer. 2023 Jul 15.
Wang MM, Coupland SE, Aittokallio T, Figueiredo CR.Br J Cancer. 2023 Jul 15.
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Bland P, Saville H, Wai PT, Curnow L, Muirhead G, Nieminuszczy J, Ravindran N, John MB, Hedayat S, Barker HE, Wright J, Yu L, Mavrommati I, Read A, Peck B, Allen M, Gazinska P, Pemberton HN, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Pratt G, Oldreive C, Stankovic T, Barlow S, Kalirai H, Coupland SE, Broderick R, Alsafadi S, Houy A, Stern MH, Pettit S, Choudhary JS, Haider S, Niedzwiedz W, Lord CJ, Natrajan R. SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. Nat Genet. 2023 Jul 31
Bland P, Saville H, Wai PT, Curnow L, Muirhead G, Nieminuszczy J, Ravindran N, John MB, Hedayat S, Barker HE, Wright J, Yu L, Mavrommati I, Read A, Peck B, Allen M, Gazinska P, Pemberton HN, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Pratt G, Oldreive C, Stankovic T, Barlow S, Kalirai H, Coupland SE, Broderick R, Alsafadi S, Houy A, Stern MH, Pettit S, Choudhary JS, Haider S, Niedzwiedz W, Lord CJ, Natrajan R. SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. Nat Genet. 2023 Jul 31
Choroidal biopsies; a review and optimised approach.
Hussain RN, Damato B, Heimann H. Eye (Lond). 2023 Apr;37(5):900-906
Hussain RN, Damato B, Heimann H. Eye (Lond). 2023 Apr;37(5):900-906
The 5th Edition of the World Health Organization Classification of Tumours of the Eye and Orbit.
Milman T, Grossniklaus HE, Goldman-Levy G, Kivelä TT, Coupland SE, White VA, Mudhar HS, Eberhart CG, Verdijk RM, Heegaard S, Gill AJ, Jager MJ, Rodríguez-Reyes AA, Esmaeli B, Hodge JC, Cree IA; WHO Classification of Tumours Editorial Board. Epub 2023 Apr 18.PMID: 37900189
Milman T, Grossniklaus HE, Goldman-Levy G, Kivelä TT, Coupland SE, White VA, Mudhar HS, Eberhart CG, Verdijk RM, Heegaard S, Gill AJ, Jager MJ, Rodríguez-Reyes AA, Esmaeli B, Hodge JC, Cree IA; WHO Classification of Tumours Editorial Board. Epub 2023 Apr 18.PMID: 37900189
A multicenter study validates the WHO 2022 classification for conjunctival melanocytic intraepithelial lesions with clinical and prognostic relevance.
Mudhar HS, Krishna Y, Cross S, Auw-Haedrich C, Barnhill R, Cherepanoff S, Eagle R, Farmer J, Folberg R, Grossniklaus H, Herwig-Carl MC, Hyrcza M, Lassalle S, Loeffler KU, Moulin A, Milman T, Verdijk RM, Heegaard S, Coupland SE. Lab Invest. 2023 Nov 2:100281.
Mudhar HS, Krishna Y, Cross S, Auw-Haedrich C, Barnhill R, Cherepanoff S, Eagle R, Farmer J, Folberg R, Grossniklaus H, Herwig-Carl MC, Hyrcza M, Lassalle S, Loeffler KU, Moulin A, Milman T, Verdijk RM, Heegaard S, Coupland SE. Lab Invest. 2023 Nov 2:100281.
[Molecular diagnostics for vitreoretinal lymphoma].
Bonzheim I, Salmerón-Villalobos J, Süsskind D, Szurman P, Gekeler F, Spitzer MS, Salaverria I, Campo E, Coupland SE, Quintanilla-Martinez L, Fend F.Pathologie (Heidelb). 2023 Nov 10. PMID: 37947807
Bonzheim I, Salmerón-Villalobos J, Süsskind D, Szurman P, Gekeler F, Spitzer MS, Salaverria I, Campo E, Coupland SE, Quintanilla-Martinez L, Fend F.Pathologie (Heidelb). 2023 Nov 10. PMID: 37947807
